KUALA LUMPUR, June 10 -- Crown Bioscience will present its new, proprietary NAFLD/NASH preclinical model development data at the American Diabetes Association (ADA) 80th Scientific Sessions, as well as CrownBio’s own complementary virtual event.
According to a statement, the new data shares development of NAFLD/NASH models generated through dietary modifications across CrownBio’s repertoire of highly translational rodent and NHP preclinical models.
The models will enable enhanced preclinical NAFLD/NASH drug development, a disease area currently lacking approved therapies.
Alongside ADA 2020 posters, CrownBio also supports the concurrent International NASH Day on June 12 with a NAFLD/NASH model development presentation.
“We’re committed to furthering and accelerating NAFLD/NASH research, by continuing to enhance our platform of highly translational preclinical models,” said CrownBio senior vice-president (cardiovascular and metabolic disease), Dr Jim Wang.
CrownBio’s virtual ADA event will take place from June 12 to 16 at CrownBio.com/ADA20.
The event allows discussion with the CrownBio cardiovascular and metabolic disease team, as well as the review and download of a wide range of resources across disease areas including NAFLD/NASH, diabetes, obesity, renal and cardiovascular diseases.
-- BERNAMA
No comments:
Post a Comment